This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Delivered as a Hybrid Event from September 20-30, 2021
Live In-Person Experience Delivered September 20-23Boston Convention and Exhibition Center

Claire Leurent, Ph.D., MBA
Principal, Venture Investments at J&J

Profile

Claire is Principal, Venture Investments at Johnson & Johnson Innovation – JJDC, Inc. (JJDC) and is based in the Johnson & Johnson Innovation Center in Boston, MA.  Claire focuses on pharmaceutical investments in areas of strategic interest to Johnson & Johnson. 

Prior to joining JJDC, Claire was Investment Director, then Managing Director, at Samsung Ventures with a focus on Life Science, Health Economics and Connected Health sectors.  Prior to Samsung Ventures, she spent 14 years in the pharmaceutical industry in R&D. At Pfizer, she led teams in design and implementation of clinical plans from First in Human to Proof of Concept studies with end-to-end accountability for various development programs ranging from small molecules and biologics to digital technologies. Prior to Pfizer, Claire supported large global multicentric phase 3 pre/registration studies and launch activities at Wyeth Pharmaceuticals in Neuroscience and Women Health. Prior to Wyeth, she was Project Manager at Forenap, a neuroscience CRO, where she advanced a portfolio of clinical protocols for diverse global pharma clients. In this position, she acquired first-hand operational experience in clinical trials and oversaw First in Human studies at the Phase 1 center. 

Claire earned her Ph.D. in molecular and cellular biology at the Institute of Genetics, Molecular and Cellular Biology (IGBMC) of Strasbourg, France. She also earned a certificate in Pharmacology from La Pitié-Salpêtrière (Paris VI), and the FIEC certificate in Clinical Trial from Louis Pasteur University (ULP, Strasbourg). She earned her MBA at MIT Sloan.

Agenda Sessions

  • ROOM 210A: Panel: Investment view on Innovation in Cell & Gene Therapy

    9:00am
  • ROOM 210A: Panel: Investment view on Innovation in Cell & Gene Therapy (Cont.)

    9:30am